Pasithea Quick Ratio from 2010 to 2025

KTTAW Stock  USD 0.02  0  9.89%   
Pasithea Therapeutics Quick Ratio yearly trend continues to be fairly stable with very little volatility. Quick Ratio will likely drop to 6.94 in 2025. Quick Ratio is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. View All Fundamentals
 
Quick Ratio  
First Reported
2010-12-31
Previous Quarter
7.31
Current Value
6.94
Quarterly Volatility
25.56915476
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 783 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 9.8 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.44. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Latest Pasithea Therapeutics' Quick Ratio Growth Pattern

Below is the plot of the Quick Ratio of Pasithea Therapeutics Corp over the last few years. It is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. Pasithea Therapeutics' Quick Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Quick Ratio10 Years Trend
Pretty Stable
   Quick Ratio   
       Timeline  

Pasithea Quick Ratio Regression Statistics

Arithmetic Mean35.69
Geometric Mean28.04
Coefficient Of Variation71.65
Mean Deviation13.00
Median37.55
Standard Deviation25.57
Sample Variance653.78
Range113
R-Value(0.22)
Mean Square Error666.96
R-Squared0.05
Significance0.42
Slope(1.17)
Total Sum of Squares9,807

Pasithea Quick Ratio History

2025 6.94
2024 7.31
2023 6.35
2022 18.15
2021 119.17

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Quick Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Quick Ratio 7.31  6.94 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.